Business Wire

CIRIUM

Share
Indian Airports Dominate Cirium’s 2023 On-Time Performance Review

Two of the top five global airports for on-time performance hailed from India this year, in Cirium’s annual On-Time Performance Review.

Rajiv Gandhi International Airport came second in the global rankings with 84.42% of flights on time, and Kempegowda International Airport hot on its heels with 84.08% of flights on time, in third place.

There was also a top place finish in the medium airports category for another APAC airport, with Osaka International Airport who managed an impressive 90.71% of flights on time. There was a second-place finish in the small airports category for Chubu Centrair International Airport (NGO) with 90.17% of flights on time, just 0.12% behind the top spot.

It should also be noted that Indigo Airlines was achieved an impressive fourth place in punctuality for the Asia Pacific Airline category with 82.12% of its flights arriving on-time. While operating nearly 680,000 flights in 2023.

An on-time flight is defined as a flight that arrives within 15 minutes of the scheduled gate arrival. For an airport, it is defined as departing within 15 minutes of its scheduled departure.

Jeremy Bowen, CEO of Cirium, said: "Cirium’s annual On-Time Performance Review is a global assessment of the punctuality of all types of carriers and airports, as evidenced by the widespread representation of operations from each corner of the globe, in this year’s review. Indian airports performed particularly well, with podium finishes in the global and large airport categories, and there was further representation for the APAC region in the other two airport categories as well. I’d like to extend my congratulations to all the featured airlines and airports in this year’s review.”

Now in its 15th year, the Cirium On-Time Performance program continues to meticulously monitor global airline operational performance. Our extensive and unbiased data, derived from over 600 real-time information sources, is essential for industry stakeholders. Our data encompasses airlines, airports, global distribution systems, civil aviation authorities, and more, ensuring a comprehensive and neutral perspective.

Cirium is continuing to lead the way, worldwide, in monitoring aviation on-time performance in the New Year, as the industry adjusts to post-pandemic norms. The company’s data and analytics are designed to provide industry stakeholders with a neutral, third-party perspective, based on the widest and deepest pool of information collected and curated from more than 600 sources of real-time flight information.

These include the airlines themselves, airports, global distribution systems, positional data, civil aviation authorities, air navigation service providers, proprietary data partnerships and the internet. Cirium’s on-time performance data is backed by a completely independent board of advisors, comprised of industry experts with an unbiased view of the aviation sector. The board’s oversight ensures accuracy and proper representation of all the information the company presents.

The top performing global airports of 2023 were:

Airport

On time ranking

On time departure

Total flights

Minneapolis-St. Paul International Airport (MSP)

1

84.44%

289,817

Rajiv Gandhi International Airport (HYD)

2

84.42%

168,426

Kempegowda International Airport (BLR)

3

84.08%

237,461

El Dorado International Airport (BOG)

4

84.01%

292,486

Salt Lake City International Airport (SLC)

5

83.99%

226,705

The top Asia Pacific Airlines of 2023 were:

Airline

On time ranking

On time arrival

Total flights

All Nippon Airways (NH)

1

82.75%

302,279

Japan Airlines (JL)

2

82.58%

308,302

Thai AirAsia (FD)

3

82.52%

113,871

IndiGo (6E)

4

82.12%

678,446

Air New Zealand (NZ)

5

79.68%

175,876

The full 2023 On-Time Performance Review is available for download at Cirium.com/on-time-performance

About Cirium

Cirium is the world’s most trusted source of aviation analytics. Through powerful data and analytics, coupled with decades of industry experience, Cirium is enabling airlines, airports, travel companies, aircraft manufacturers, and financial institutions, amongst others, to make intelligent and informed decisions that improve operations, grow revenues, and enhance customer experiences.

Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.

For further information please follow Cirium updates on LinkedIn or visit www.cirium.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240116289335/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee

DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release

Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc

Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release

SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f

Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press release

Through the Extreme Exchange (IX) acquisition, Megaport gains seven Internet Exchanges and access to 40+ data centres across India’s fastest-growing digital hubs. Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly thr

IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 22:10:00 CET | Press release

Extension solidifies QuantumBasel as IonQ’s Innovation Center in Europe; adds IonQ Tempo and next-generation system to advance quantum commercialization IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerston

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye